We consider the design of an experiment involving two drugs; associated with each drug is an identifiable type of toxicity. For example, in cancer chemotherapy, cyclophosphamide is toxic to the heart and busulfan is toxic to the liver. Therefore, four responses are possible: no toxicity, toxicity to the heart, toxicity to the liver and toxicity to both organs. Consequently, responses are bivariate binary random variables that depend on a bivariate treatment space. Assuming a bivariate probit response function with $0\le\rho\le1,$ we have shown that the D-optimal design consists of 4 points with equal allocation to each. These 4 points are not unique. Indeed, given a standardized design space, any four equidistant points inscribed in a circl...
Nonlinear regression models addressing both efficacy and toxicity outcomes are increasingly used in...
estimating the underlying dose-response curve for a restricted or unrestricted dose range with respe...
The present paper deals with the problem of allocating patients to two competing treatments in the p...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
A Bivariate Optimizing Up-and-Down design for selecting the drug combination with maximum success pr...
We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials...
We consider a bivariate logistic model for a binary response, and we assume that two rival dependenc...
One of the most complex tasks during the clinical development of a new drug is to find a correct dos...
Algorithms for finding optimal designs for three-parameter binary dose–response models that incorpor...
grantor: University of TorontoMethods of statistical inference are developed which can be ...
Pharmacodynamics (PD) is the study of the biochemical and physiological effects of drugs. The constr...
A common problem in Phase II clinical trials is the comparison of dose response curves corresponding...
This thesis covers three related topics in the optimal design of experiments, with applications to c...
The response of a patient in a clinical trial usually depends on both the selected treatment and som...
We consider the problem of optimal design of experiments for random-effects models, especially popul...
Nonlinear regression models addressing both efficacy and toxicity outcomes are increasingly used in...
estimating the underlying dose-response curve for a restricted or unrestricted dose range with respe...
The present paper deals with the problem of allocating patients to two competing treatments in the p...
In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/...
A Bivariate Optimizing Up-and-Down design for selecting the drug combination with maximum success pr...
We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials...
We consider a bivariate logistic model for a binary response, and we assume that two rival dependenc...
One of the most complex tasks during the clinical development of a new drug is to find a correct dos...
Algorithms for finding optimal designs for three-parameter binary dose–response models that incorpor...
grantor: University of TorontoMethods of statistical inference are developed which can be ...
Pharmacodynamics (PD) is the study of the biochemical and physiological effects of drugs. The constr...
A common problem in Phase II clinical trials is the comparison of dose response curves corresponding...
This thesis covers three related topics in the optimal design of experiments, with applications to c...
The response of a patient in a clinical trial usually depends on both the selected treatment and som...
We consider the problem of optimal design of experiments for random-effects models, especially popul...
Nonlinear regression models addressing both efficacy and toxicity outcomes are increasingly used in...
estimating the underlying dose-response curve for a restricted or unrestricted dose range with respe...
The present paper deals with the problem of allocating patients to two competing treatments in the p...